source
- FDA approves Rasonque, first-in-class RAS inhibitor for metastatic pancreatic cancerThe U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a RAS inhibitor, for the treatment of metastatic pancreatic adenocarcinoma. Rasonque is a tablet taken once daily that t…
- Biohaven sells rights to its lead epilepsy drug opakalim to SK Biopharma for up to $795 millionBiohaven announced it will transfer the rights to its most advanced experimental therapy for focal epilepsy, known as opakalim, to South Korean company SK Biopharma. The agreement could bring as m…